Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Credit Suisse Lux Biotechnology Equity Fund

+ Add to Watchlist

C27B:GR

317.5400 EUR 7.0800 2.28%

As of 02:41:59 ET on 03/05/2015.

Snapshot for Credit Suisse Lux Biotechnology Equity Fund (C27B)

Open: 315.2800 High - Low: 317.6900 - 315.2700 Primary Exchange: Dusseldorf
Volume: 0 52-Week Range: 197.4300 - 317.6900 Beta vs NBI: 0.9427

ETF Chart for C27B

No chart data available.
  • C27B:GR 317.6900
  • 1D
  • 1M
  • 1Y
310.4600
Interactive C27B Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for C27B

Credit Suisse Lux Biotechnology Equity Fund is a SICAV incorporated in Luxembourg. The Fund is actively managed aiming to outperform the return of the NASDAQ Biotechnology TR benchmark. The Fund mainly invests in equity and equity-type securities of issuers engaged in the biotechnology industry.

Inception Date: Telephone: -
Managers: IRENE BEATRICE PUETTNER
Web Site: www.credit-suisse.com

Fundamentals for C27B

NAV (on 2015-03-03) 316.3700
Assets (M) (on 2015-03-03) 252.0568
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium -3.09
Average 52-Week % Premium -0.9156
Fund Leveraged N

Dividends for C27B

No dividends reported

Performance for C27B

1-Month +8.32% 1-Year +27.10%
3-Month +11.47% 3-Year -
Year To Date +10.83% 5-Year +27.47%
Expense Ratio -

Top Fund Holdings for C27B

Filing Date: 12/31/2014
Name Position Value % of Total
Amgen Inc 105,973 16,880,439 7.501%
Celgene Corp 150,276 16,809,873 7.470%
Gilead Sciences Inc 162,484 15,315,742 6.806%
Biogen Idec Inc 44,745 15,188,690 6.749%
Regeneron Pharmaceuticals Inc 27,000 11,076,750 4.922%
Vertex Pharmaceuticals Inc 90,000 10,692,000 4.751%
Incyte Corp 145,000 10,600,950 4.711%
BioMarin Pharmaceutical Inc 115,444 10,436,138 4.637%
Alexion Pharmaceuticals Inc 52,752 9,760,703 4.337%
Medivation Inc 80,000 7,968,800 3.541%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil